OOIR: Observatory of International Research

Papers

(The H4-Index of Drug Discovery Today is 53. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Transitioning biomedical research toward human-centric methodologies: systems-based strategies	199
A new approach to treat type 2 diabetes – Targeting a non-insulin dependent pathway	189
Molecular biomarkers of glial activation and injury in epilepsy	180
Contents page	168
Artificial intelligence (AI) and alternative variables (AV) in drug discovery: A promising alliance	128
The epigenetic impact of fatty acids as DNA methylation modulators	126
Polysaccharides as therapeutic vehicles in pancreatic cancer	122
Contents page	109
Therapies for Inherited Retinal Dystrophies: What is Enough?	108
Trends in small molecule drug properties: A developability molecule assessment perspective	107
Nanofibers as drug-delivery systems for antimicrobial peptides	98
Redox active or thiol reactive? Optimization of rapid screens to identify less evident nuisance compounds	97
The recent progress of deep-learning-based in silico prediction of drug combination	96
Strengthening Molecular Glues: Design Strategies for Improving Thalidomide Analogs as Cereblon Effectors and Anticancer Agents	96
The ethics of animal research and testing: A US perspective	95
Contents page	93
Neoteric solvents for the pharmaceutical industry: an update	89
A personalized pharmaco-epistatic network model of precision medicine	86
Generative AI: driving productivity and scientific breakthroughs in pharmaceutical R&D	85
Corrigendum to “A review of in vitro and in vivo methods and their correlations to assess mouthfeel of solid oral dosage forms” [Drug Discov. Today 26(3) (2021) 740–753]	81
Fiduciary responsibility	79
Contents page 2	79
Contents page 2	78
Overlapping biosimilar and originator follitropin alfa preparations: How much closer can they get?	75
Crystallographic landscape provides molecular insights into the modes of action of diverse ROR-γt modulators	75

Drug discovery for epigenetics targets	74
Generic dry powder inhalers bioequivalence: Batch–to-batch variability insights	71
Trends, challenges, and success factors in pharmaceutical portfolio management: Cognitive biases in decision-making and their mitigating measures	71
Contents page 1	71
Industry perspective on the nonclinical safety assessment of heterobifunctional degraders	69
The promise of crowdfunding to finance R&D of novel diagnostics and therapeutics for incurable diseases	67
Comparative analysis of FDA approvals by top 20 pharma companies (2014–2023)	67
Advancements in small molecule drug design: A structural perspective	66
Neurotrophin-targeted therapeutics: A gateway to cognition and more?	65
Antibody–drug conjugates: What drives their progress?	64
Improving the ability of antimicrobial susceptibility tests to predict clinical outcome accurately: Adding metabolic evasion to the equation	64
Four scenarios for the future of medicines and social policy in 2030	63
An exploration of alternative therapeutic targets for aortic disease in Marfan syndrome	63
Contents page	63
How can we unleash the potential of external controls in clinical trials?	62
Contents page	61
Innovation in breakthrough drugs and vaccines: Development risk, patient impact, and value	60
A pleiotropic–epistatic entangelement model of drug response	60
Fighting AMR with Host Immune Response Technology	60
The potential value of 5-androstenediol in countering acute radiation syndrome	59
Engineered nanomaterials as an effective tool for HER2+ breast cancer therapy	58
Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners	58
Graph neural networks for automated de novo drug design	57
Integrating heterogeneous data to facilitate COVID-19 drug repurposing	55
Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights	55
Opportunities and challenges in drug discovery targeting the orphan receptor GPR12	54
Biopharmaceutical R&D outsourcing: Short-term gain for long-term pain?	54
Therapeutic potential of glutaminyl cyclases: Current status and emerging trends	54
Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2	53
Natural products in pursuing novel therapies of nonalcoholic fatty liver disease and steatohepatitis	53